← Evidence map

ArticleFrontiers in oncology2026

Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study.

Lulin Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study. | OpenQuestion